Joint Filing Agreement
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Aeglea BioTherapeutics, Inc., a Delaware corporation and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.
This Joint Filing Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original instrument, but all of such counterparts together shall constitute one agreement.
In evidence thereof, the undersigned, being duly authorized, hereby execute this Joint Filing Agreement as of May 14, 2018.
| /s/ Xxxx Xxxxxxxxx | ||
|
Name: Xxxx Xxxxxxxxx
|
||
|
Title: Secretary of the Board
|
||
| /s/ Xxxxxxx Xxxxxxxxx | ||
|
Name: Xxxxxxx Xxxxxxxxx
|
||
|
Title: Authorized Signatory
|
||
|
Novartis AG
|
||
| /s/ Xxxx Xxxxxxxxx | ||
|
Name: Xxxx Xxxxxxxxx
|
||
|
Title: Authorized Signatory
|
||
| /s/ Xxxxxxx Xxxxxxxxx | ||
|
Name: Xxxxxxx Xxxxxxxxx
|
||
|
Title: Authorized Signatory
|
